1.14
0.06 (5.56%)
| Previous Close | 1.08 |
| Open | 1.08 |
| Volume | 21,499 |
| Avg. Volume (3M) | 101,008 |
| Market Cap | 14,010,867 |
| Price / Earnings (Forward) | 1.00 |
| Price / Sales | 0.370 |
| 52 Weeks Range | |
| Earnings Date | 25 Mar 2026 |
| Profit Margin | -86.05% |
| Operating Margin (TTM) | -130.50% |
| Diluted EPS (TTM) | -14.22 |
| Quarterly Revenue Growth (YOY) | -40.50% |
| Quarterly Earnings Growth (YOY) | 32.10% |
| Current Ratio (MRQ) | 2.09 |
| Operating Cash Flow (TTM) | -43.13 M |
| Levered Free Cash Flow (TTM) | -20.05 M |
| Return on Assets (TTM) | -52.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Allurion Technologies, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.63 |
|
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 11.67% |
| % Held by Institutions | 46.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rtw Investments, Lp | 31 Dec 2025 | 5,891,430 |
| Lunt Capital Management, Inc. | 31 Dec 2025 | 166,666 |
| Anson Funds Management Lp | 31 Dec 2025 | 59,881 |
| Empery Asset Management, Lp | 31 Dec 2025 | 59,881 |
| Hudson Bay Capital Management Lp | 31 Dec 2025 | 59,880 |
| L1 Global Manager Pty Ltd | 31 Dec 2025 | 59,880 |
| Heights Capital Management, Inc | 31 Dec 2025 | 59,880 |
| Unisphere Establishment | 31 Dec 2025 | 49,695 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices |
| 12 Jan 2026 | Announcement | Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results |
| 25 Nov 2025 | Announcement | Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |